BASEL, SWITZERLAND--(Marketwire - May 20, 2008) -
Basilea Pharmaceutica Ltd. (SWX: BSLN) highlights the presentation of positive phase III results on ceftobiprole in the treatment of community-acquired pneumonia (CAP) requiring hospitalization at the International Conference of the American Thoracic Society (ATS). The detailed analysis of previously announced top line results demonstrate high cure rates in patients at risk for poor outcomes.
